Parkinson Canada now invites individuals living with Parkinson’s disease to join the Canadian Open Parkinson Network (C-OPN), a solution to improve lives for those living with Parkinson’s and ultimately to help discovery a cure. Phase One of the Registry & Biobank...
Parkinson’s Disease
Category
University of Helsinki Researchers Find a Molecule (BT13) that has Therapeutic Potential Against Parkinson’s Disease
University of Helsinki researchers made a breakthrough in their discovery that a molecule known as BT13 has the potential as a therapeutic for Parkinson’s disease. In preclinical research studies including in vitro and in vivo studies in mouse models, the Finnish team...
University College London-Led Study Reveals Ambroxol Evidences Promise as Parkinson’s Disease Drug
A team led by University College London Institute of Neurology discovered ambroxol therapy could be used as a neuroprotective compound to treat patients with Parkinson’s disease both with and without glucocerebrosidase (GBA1) gene mutations. This study was sponsored...
Feinstein Institutes for Medical Research Developed Parkinson’s Disease PET Drug
The Feinstein Institutes for Medical Research has received U.S. Food and Drug Administration (FDA) approval for a new Positron Emission Tomography (PET) drug to combat Parkinson’s disease. Fluorodopa F 18 Injection (NDA 200655) will help visualize dopaminergic nerve...
George Washington University Study Asks: Can Nilotinib be Repurposed from use for Specific Cancer to use for Parkinson’s Disease?
There is tremendous value in identifying new purposes for existing drugs. Recently, Georgetown University Medical Center (GUMC) embarked on a project to do just that for Parkinson’s disease with a cancer drug called nilotinib (Tasigna). They found that the drug in...
Northwestern University Center for Neurogenetics Developed S-181 Evidences Promise for Addressing Parkinson’s Disease
Researchers from the Center for Neurogenetics and colleagues from the Northwestern University Feinberg School of Medicine report a novel small-molecule modulator called S-181 shows promise in preclinical research animal studies for the treatment of a familial form of...
Researchers Report Growing Gene Therapy Momentum in Neurodegenerative Drug Development Field
Gene therapy is making a comeback in the world of neurodegeneration research, as evidenced by this year’s Society for Neuroscience conference held in Chicago. With the success of Novartis Zolgensma (gene therapy for spinal muscular atrophy in infants), money...
In the Future, Computers Could Facilitate Neurological Condition Monitoring and Diagnoses
Imagine having a stroke or Parkinson’s disease and how difficult it could be to get to a doctor’s appointment. Or being in a remote part of the world where medical facilities are few and far between. Having a video clip of your movements being reviewed and diagnosed...
Gene Therapy Shows Potential for Parkinson’s Disease
Parkinson’s disease spells big trouble for the U.S. and its growing population of aging baby boomers. The ailment may affect over 1 million Americans with 50,000 to 60,000 new diagnosed cases per year. An investigator at the Center for Neurosciences at the Feinstein...
UPenn CNDR Receives $18M to Study Underlying Genetic Mechanisms of Alzheimer’s, Dementia & Parkinson’s Disease
The Center for Neurodegenerative Disease Research (CNDR) at the University of Pennsylvania received $18.1 million to study the underlying genetic mechanisms that caused Alzheimer’s Disease, Dementia, and Parkinson’s Disease to progress as well as how those mechanisms...
How Clinical Trials from Home Can Increase Access to Life-Changing Treatments
Some 85% of people over 60 use prescription drugs, according to the National Center for Health Statistics (NCHS). Yet, older people are not well represented in clinical trials, the gold standard for testing the safety and efficacy of medications, the NCHS says. The...
Northwestern Medicine Team Eliminate Parkinson’s Disease Symptoms in Human Brain Cells & Mouse Models
Northwestern Medicine researchers, led by Dr. Dimitri Krainc, used patient-derived neurons to develop and test a novel strategy to treat Parkinson’s disease by mitigating the effects of harmful mutations. Taking a different approach, the Chicago-based group sought to...
Parkinson’s UK & King’s College London Plan Pioneering Clinical Trial to Treat Psychosis in Parkinson’s Patients Using Cannabidiol
Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, has partnered with investigators at King’s College London to invest £1.2 million in a pioneering Phase II clinical trial investigating the use of cannabidiol (CBD)—a compound found...
Fresno, CA Clinical Investigative Site Neuro-Pain Medical Center Enrolling Patients in Sunovion’s Parkinson’s Disease Study
Neuro-Pain Medical Center is seeking patients for a clinical trial evaluating an investigational medication for people diagnosed with Parkinson’s disease who are experiencing conditions such as seeing and hearing things that may not be there. The study will help to...
JEM Research Institute Seeks Participants for Sunovion’s Investigational Treatment for Parkinson’s Disease Psychosis Clinical Trial
Clinical investigative Site JEM Research Institute, based in Atlantis, Florida, seeks participants for a clinical trial evaluating an investigational medication in people diagnosed with Parkinson’s disease who are experiencing symptoms such as seeing and hearing...
Investigators Identify Possible Diagnostic Tool & Treatment for Parkinson’s Disease
Investigators at the Stanford University School of Medicine have identified a molecular defect that appears to be universal to Parkinson’s disease as well as those at risk of becoming afflicted with the neurodegeneration disease. This discover may pave the way...
CereHealth Brain Imaging Centers Selected by Denver Neurological Research for SPARC Phase II Parkinson’s Trial
CereScan,® (CereHealth Corporation), a national network of functional brain imaging and analytics centers, have received approval of its Littleton, CO, location as a qualified imaging facility for a Sun Pharma Advanced Research Company (SPARC) sponsored Phase II,...
Phase 3 Trial Initiated to Test Investigational Drug for People with Parkinson’s Disease Experiencing Motor Fluctuations
Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced the initiation of the Phase 3 BouNDless study investigating the efficacy, safety and tolerability of ND0612, a potential non-surgical, subcutaneous continuous treatments, compared to oral immediate-release...
Suncoast Neuroscience Associates Conducting Parkinson’s Clinical Trial in Florida for Parkinson’s Disease Patients Exhibiting Hallucinations and Delusions.
Suncoast Neuroscience Associates, a dedicated clinical investigational site, is actively recruiting participants for a clinical research study to evaluate an investigational medicine in people diagnosed with Parkinson’s disease exhibiting hallucinations and delusions....
Oxford University-Originated Gene Therapy Targeting Parkinson’s Disease in Early Stage Clinical Trials
In preclinical research, investigational gene therapy AXO-Lenti-PD (OXB-102) was seen to be both safe and effective in a primate model of Parkinson’s disease based on study results from Oxford Biomedica and partner Axovant Sciences. A clinical trial is now underway....